Resection of colorectal liver metastases.
LiDCOrapid as part of an enhanced recovery program (ERAS).
Before v after an ERAS introduction.
The probability that LOS would be > 10 days decreased to 7% from 25% & ICU utilization reduced from 75.5% to 54.7%.
There is limited evidence for the use of enhanced recovery after surgery (ERAS) in patients undergoing hepatectomy, and the impact of the evolution of ERAS over time has not been examined. This study sought to evaluate the effect of an evolving ERAS program in patients undergoing hepatectomy for colorectal liver metastases (CRLM).
A multimodal ERAS program was introduced in 2/2008. Consecutive patients undergoing hepatectomy for CRLM between 2/2008 and 9/2012 were included in the study. Data were collected prospectively. Retrospective analysis compared an early ERAS cohort (2/2008-4/2010) with a later cohort with a matured ERAS program (5/2010-8/2012).
Length of stay reduced as experience of ERAS increased (Log-rank χ(2) = 10.43, P = 0.001). Although median length of stay remained unchanged (6 days), the probability of hospitalisation beyond 10 days was 25% in the early cohort compared with 7% in the later cohort. Critical care utilization reduced over time (75.5% vs. 54.7%, P < 0.0001). Complications occurred in 38.2%, with no difference in between cohorts. One postoperative death occurred in the early cohort (<0.3%).
This study suggests that as the experience of ERAS evolves, there is a progressive reduction in hospitalisation and critical care admission. This is without any increase in morbidity and mortality.
Dunne DF, Yip VS, Jones RP, McChesney EA, et al. Enhanced recovery in the resection of colorectal liver metastases. J Surg Oncol. 2014. doi:10.1002/jso.23616
Study showed probability that LOS would be > 10 days decreased to 7% from 25% & ICU utilization reduced from 75.5% to 54.7%.